On Tuesday OXiGENE Inc (NASDAQ:OXGN)’s shares enhanced 3.27%, and closed at $1.58, as the OXiGENE, Inc. declared that the corporation will take part in two forthcoming investor and medical conferences. Dai Chaplin, Ph.D., president and chief executive officer, will provide a corporate overview at the 14th Annual Needham Healthcare Conference on April 15, 2015. The presentation will take place at 3:00 p.m. ET at The Westin NY Grand Central Hotel in New York, NY.
Poster presentations related to OXiGENE’s early stage scientific programs will also be presented at the AACR Annual Meeting 2015 taking place April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.
OXiGENE, Inc., a clinical-stage biopharmaceutical corporation, develops therapeutics primarily to treat cancer. The corporation focuses on developing vascular disrupting agents (VDAs) that disrupt abnormal blood vessels associated with solid tumor progression.
Juniper Networks, Inc. (NYSE:JNPR), inclined 3.17%, and closed at $23.42, as on April 6, 2015, Juniper Networks the industry leader in network innovation, confirmed it will release preliminary financial results for the quarter ended March 31, 2015, on April 23, 2015 after the close of the market and will host a conference call at 2:00 p.m. PDT (Pacific Daylight Time), to be broadcast live over the Internet.
Juniper Networks, Inc. designs, develops, and sells high-performance network products and services worldwide. It provides various routing products, counting ACX series universal access routers to deploy new high-bandwidth services; MX series Ethernet routers that functions as a universal edge platform; M series edge routers; PTX series packet transport routers; and T series routers.
At the end of Tuesday’s trade, Celldex Therapeutics, Inc. (NASDAQ:CLDX), surged 3.07%, and closed at $27.19, as the Celldex Therapeutics, Inc. disclosed that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, counting breast cancer. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome.
Celldex Therapeutics, Inc., a biopharmaceutical corporation, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The corporation’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma.
Baytex Energy Corp (USA) (NYSE:BTE), gained 3.03%, and closed at $17.69, as the Baytex Energy Corp. has closed the formerly declared bought deal financing. Baytex issued 36,455,000 ordinary shares (the “Ordinary Shares”), counting 4,755,000 ordinary shares following the full exercise of the over-allotment option, at a price of $17.35 per share for aggregate gross proceeds of about $632.5 million. The net proceeds from the Equity Financing will be used to reduce bank indebtedness, raise working capital and fund ongoing capital expenditures.
Baytex Energy Corp., an oil and gas corporation holds in the attainment, development, exploitation, and production of oil and natural gas in the Western Canadian Sedimentary Basin and the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
